ClinicalTrials.gg
RecruitingNCT07567560Updated Aug 7, 2026

The Short Sleep Study

An observational study in Short Sleepers, sponsored by Danisco. Recruiting at 4 sites in United States. Open to participants aged 20 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by Danisco (part of International Flavors & Fragrances Inc.) · Observational

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
34
Ages
20 Years to 50 Years
Sex
All
01

Study summary

Natural Short Sleepers are defined as individuals who sleep fewer than 6 hours per night without any impact on health or daytime mental fatigue levels. Emerging evidence suggests that, in the general population, the gut microbiota would be negatively influenced by this sleep duration. It is possible that Natural Short Sleepers have a distinct gut microbiome. Identifying differences in microbiota composition may lead to an opportunity to improve health outcomes in those with inadequate or poor sleep.

02

Conditions studied

  • Short Sleepers

Keywords

  • short sleep
  • short sleepers
03

In context

Lead sponsor

Danisco is the lead sponsor of 24 studies on the registry; 2 are open to participants now.

First submitted after Danisco became part of International Flavors & Fragrances Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Natural Short Sleepers are defined as individuals who sleep between 4 and 5.5 hours per night without any impact on health or daytime mental fatigue levels.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men between 20 - 50 years of age and pre-menopausal women between 20 - 45 years of age (inclusive).
  2. Consistent schedule during daytime hours.
  3. (BMI) 18.5 - 35 kg/m2 (inclusive).
  4. Good physical and mental health as established by self-reported medical history and evaluated by a study investigator.
  5. Willingness to maintain and record their general habits, eating, and daily activity/exercise pattern for the study period.
  6. Willingness to maintain typical sleep hygiene patterns (e.g. sleep location, temperature, environment).
  7. Willingness to maintain their current pattern of alcohol consumption for the duration of the study.
  8. Willing and able to participate fully in all aspects of the study and complete all study procedures, including providing signed .
  9. Willing and able to attend two in-person visits at a trial site
  10. Completes all required procedures (screening questionnaire and ePROs) during the 14-day screening period 10a. Two instances of the sleep diary and Karolinska Sleepiness Scale may be missed by the participant without impacting eligibility
  11. Has regular bowel habits, on at least 5 days a week.
  12. Pittsburgh Sleep Quality Index (PSQI) global score of ≤7 and a sleep efficiency score of ≥80%, self-reported during the screening period. Additionally, no more than one score of 3 is permitted across Question 5 sub-items, and no score of 3 is permitted in Question 10 sub-items, if a bed partner is present
  13. Sleep, on average, 4-5.5 hours per night, verified via participant self-report during the screening period. If the participant's average is within the 4-5.5 hour range but slept more than 5.5 hours on any of the nights their eligibility will be assessed per PI/Sponsor discretion. Note: Oura ring data from the run-in period will be reviewed to confirm eligibility based on PI/Sponsor discretion.
  14. Report feeling refreshed with no desire to nap during the daytime, with a score of ≤4 on the Epworth Sleepiness Scale (ESS) evaluated during the screening period.
  15. Average KSS Score of 1-3 during the screening period.

Exclusion criteria

Exclusion:

  1. Ever diagnosed with or self-reports a sleep disorder, including sleep apnea, habitual snoring (defined as loud, persistent snoring 3 or more nights per week), insomnia, narcolepsy, or parasomnias.
  2. Extreme chronotypes, those who regularly go to sleep prior to 8:00pm.
  3. Any current diagnosed or self-reported gastrointestinal disorder, including Crohn's disease, ulcerative colitis, celiac disease, IBS, or functional bowel disorder or chronic heartburn.
  4. Regularly wakes up during the night 5 or more times per night for a cumulative amount of 30 minutes as observed via self-report during the screening period, per PI discretion.
  5. Currently taking medications (including over-the-counter medications) or dietary supplements that, in the investigator's opinion, may affect the participants' microbiome or sleep.
  6. Have taken in the last 3 months medications (including over-the-counter medications) or dietary supplements that, in the investigator's opinion, may affect the participants' microbiome or sleep.
  7. Neurodegenerative diseases (including multiple sclerosis, Parkinson's disease, Alzheimer's disease, dementia).
  8. Recent history (past year) of alcohol abuse or dependence. Defined as regularly drinking more than 12 drinks for females and more than 20 drinks for males per week and based on PI discretion.
  9. Drug abuse or dependence, including consistent recreational substance use such as marijuana.
  10. Binge drinking behavior, defined as 4 or more alcoholic drinks for women or 5 or more alcoholic drinks for men in one sitting on 2 or more occasions, within the past 1 month with final decision per PI discretion.
  11. Recent history (current use or within the past 1 month) of smoking, vaping or other use of nicotine-containing products.
  12. Diagnosed neuropsychiatric disorders or symptoms possibly affecting sleep e.g. (generalized anxiety disorder (GAD), major depressive disorder (MDD), bipolar disorder, schizophrenia)
  13. Any use of systemic antibiotics in the past 3 months. This does not include topical or targeted antibiotic use (ointment, spray, eye drop, ear drop).
  14. Any use of probiotic supplements in the past 2 weeks.
  15. Any use of proton pump inhibitors (PPIs) in the past 2 weeks.
  16. Any use of laxatives or antidiarrheals in the past 4 weeks.
  17. Any use of non-steroidal anti-inflammatory drugs (NSAIDs) for 5 or more consecutive days in the past 4 weeks.
  18. Pregnant or breastfeeding or planning to become pregnant.
  19. Personal circumstances affecting stress or sleep (e.g. serving as a caretaker/required to wake up during sleep/major change in personal life). Note: Life situations causing stress or challenges in sleep that are considered shortterm, per PI discretion, may be considered for re-screening 4 weeks after the life situation has resolved, meaning it is no longer causing stress or challenges in sleep.
  20. Planned overnight travel during the study.
  21. Females experiencing perimenopausal or menopausal symptoms, or those who have been diagnosed as perimenopausal or menopausal by a physician.
  22. Any diagnosed condition or undiagnosed symptom which disrupts sleep, including, but not limited to, hyperthyroidism, night sweats, restless legs, or poorly controlled allergic rhinitis.
  23. Varying work schedule and/or shift workers who work overnight shifts (e.g. 3rd shift, working late night to early morning hours).
  24. Any other personal or medical condition that the investigator believes may bias or confound the results.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
34 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Natural Short Sleepers

    Natural short sleepers (NSS) sleep on average \<6 hours per night, but feel no need to sleep longer, and do not show signs of daytime sleepiness or fall asleep in low stimulus environments.

06

What researchers measure

Primary outcomes

  1. Microbiome characterization of the short sleeper population

    Identify a specific fecal microbiota composition related to short sleep

    Time frame: baseline through day 10 of the study period.

  2. Comparison of natural short sleeper microbiomes to participants from the night owl study.

    Compare microbiome (composition and function) of natural short sleeprs to those individuals enrolled into the night owl study.

    Time frame: From baseline through day 10 of the study period.

07

Study locations

4 of 4 sites recruiting
  • Global Life Research Network
    Miami, Florida 33155, United States
    Recruiting
  • Lindus Health
    Boston, Massachusetts 02111, United States
    Recruiting
  • AccuMed
    Garden City, New York 11530, United States
    Recruiting
  • New Dawn Wellness and Medical Research Center
    Houston, Texas 77082, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Dec 2026, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2025
First posted
May 5, 2026
StartActual
Oct 23, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Apr 2027
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07567560
Lead sponsor
Danisco
Responsible party
Sponsor
First posted
May 5, 2026
Start date
Oct 23, 2025
Primary completion
Dec 2026 (estimated)
Completion
Apr 2027 (estimated)
Last update
Aug 7, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion